Angelini Ventures
Angelini Ventures reinvests in CoMind, joining $60 Million round and bringing total funding to $102.5 Million
Angelini Ventures announces its follow-on investment participation in CoMind's latest $60 million funding round, bringing the UK-based neurotechnology company's total capital raised to $102.5 million. This investment reinforces Angelini Ventures' strategic commitment to advancing brain health, building on its co-lead role in CoMind's 2023 Series A round.
CoMind is developing revolutionary optical brain sensing technology that enables non-invasive, continuous monitoring of critical brain health parameters. The company's flagship product, CoMind One, represents a breakthrough in bedside brain monitoring—capable of measuring cerebral blood flow, cerebral autoregulation, and intracranial pressure simultaneously, something never before possible without surgery.
This follow-on investment validates the early conviction we had in CoMind's visionary team when we co-led their Series A round in 2023. What started as backing a bold idea is now evolving into a concrete opportunity to revolutionize brain monitoring with genuine patient impact. For Angelini Ventures, advancing brain health is a strategic priority, and CoMind represents the perfect complement to our biotech and drug discovery portfolio, bringing a revolutionary medtech solution that will have tangible impact on millions of patients.
Elia Stupka,
The new funding will accelerate CoMind One's path to US regulatory approval and support clinical trials, team expansion, and manufacturing partnerships. The technology has applications across intensive care units, operating rooms, and neuro-critical environments, with potential to benefit millions of patients globally.
Read the press release here: